On October 15, 2026, Longevity Technology reported that Lovehoney Group had launched the women’s-health brand SheHerMe with MenoPulse as its debut product. The device was described as available that day through more than 250 Boots stores in the UK and online.
Why established menopause care remains the reference point
The launch enters a landscape in which hormone replacement therapy remains the best-evidenced treatment for menopausal symptoms, according to Longevity Technology’s account. That account also notes that it does not suit every person or every symptom.
MenoPulse therefore raises a narrower question than whether sexual stimulation should replace hormone treatment: what evidence supports the particular benefits being marketed? Sexual wellbeing deserves serious attention in menopause care. Taking it seriously also means distinguishing an intimate product from a treatment supported by clinical evidence.
How to read the reported MenoPulse findings
- The product uses targeted stimulation rather than conventional vibration. Longevity Technology describes MenoPulse as using targeted clitoral air-pulse stimulation through Lovehoney’s Air-Pulse technology. It is marketed as a hormone-free option for menopausal wellbeing. That description identifies the approach being sold; it does not establish how effectively the device addresses a particular symptom. A preference for a hormone-free product and evidence that it treats a condition are separate questions.
- The headline percentage describes a broad reported outcome. The launch account describes a four-week user study involving 66 women aged 40 to 75. It reports that 92.9% experienced improvement in at least one menopausal symptom. “At least one” matters because the account describes an extensive symptom list. The figure does not mean that this proportion improved across all symptoms or that an individual buyer has the same likelihood of benefit.
- The study’s public description leaves the treatment question unresolved. The account does not establish a control group, randomization, blinding or a comparator. It also does not identify which symptoms improved most or whether changes persisted after use stopped. Without a described comparison group, the changes cannot be separated from natural symptom fluctuation, expectation or increased attention to participants’ bodies.
The company’s research was described as conducted with the Kinsey Institute. However, the account supplies neither an individual researcher’s name nor a peer-reviewed publication citation for the MenoPulse research. A useful next step would be a publicly described controlled study specifying the symptoms measured and the comparison condition. Follow-up after use would help address whether any benefit lasts beyond the study period.
- A plausible biological explanation is not the same as a demonstrated benefit. Longevity Technology discusses arousal-related blood flow, orgasm-associated chemical release and changes in autonomic activity. These offer possible explanations for why sexual activity might influence someone’s immediate experience. They are not proof that a particular device treats menopause symptoms. The useful question is whether the proposed mechanism translates into a meaningful outcome for the concern being addressed.
Why the particular symptom matters more than the mode name
- The modes describe intended outcomes. MenoPulse has four named modes: Sleep, Moisture, Relax and Well-being. According to the launch account, these names should be read as intended outcomes rather than separately demonstrated clinical effects. A setting called Sleep is not itself evidence of a sleep treatment. The same distinction applies to Moisture and the broader language of wellbeing.
- Temporary lubrication and persistent dryness are different claims. The account distinguishes lubrication associated with arousal from ongoing vaginal dryness or tissue changes linked to declining estrogen. It says repeated device use has not been established as a treatment for genitourinary syndrome of menopause. That distinction leaves room for an intimate product to have personal value without assigning it a medical role the evidence has not demonstrated. Comfort during sexual activity and care for persistent symptoms should not be collapsed into a single product promise.
- Relaxation on a particular night is not the whole sleep question. Longevity Technology notes that relaxation after orgasm might help someone fall asleep on a particular occasion. It also distinguishes that possibility from sleep disruption driven by night sweats or hormonal changes. The practical point is to identify what “better sleep” means in the claim. Feeling relaxed after sexual activity and addressing a recurring source of disrupted sleep are not interchangeable outcomes.
- The sexual-activity finding needs careful interpretation. The launch account says symptom levels were reportedly lowest during periods of regular sexual activity, particularly when orgasm occurred. This is an association within the reported experience, not a reason to turn sexual activity into a symptom-management obligation. Pleasure can matter on its own terms without needing a medical justification. Readers wanting broader context can turn to Refemina’s coverage of midlife desire beyond a single explanation.
These distinctions are useful because the product brings several different concerns under one menopause-wellbeing label. Arousal, comfort and sleep each deserve language precise enough to make the claim understandable. There is no need to dismiss sexual wellbeing to ask for that precision. Equally, there is no need to call an enjoyable experience a treatment for it to have value.
How to assess the launch beyond its headline result
- Separate retail availability from clinical validation. The Boots distribution reported by Longevity Technology tells readers where the device was available. It does not answer whether the product has demonstrated a particular therapeutic effect. Shelf availability and research findings serve different purposes in a purchasing decision. The more a product’s appeal rests on symptom relief rather than personal enjoyment, the more relevant the supporting evidence becomes.
- Look closely at what the planned app would recommend. Longevity Technology reports that SheHerMe planned a companion app intended to track symptoms, offer personalized recommendations and connect with the company’s hardware. Further products were planned for 2027. These were plans described in the launch account, not confirmation that the app and additional products were already available.
The account raises a useful commercial question: would recommendations include options beyond products sold by the brand? That question matters when interpreting the scope of any advice the app might provide. Tracking information and directing someone toward a purchase are different functions. Readers deserve to understand how those functions fit together before treating personalized language as a sign of clinical authority.
- Keep wider technology coverage separate from product evidence. HealthyWomen’s October 15, 2026 article, “Menopause Tech Is Getting Smarter About the Symptoms Women Live With,” places menopause technology within a discussion of women’s lived symptoms. That is a useful editorial starting point for assessing this launch too. The measure of a claim should be the concern it addresses and the evidence behind it. Attention to a technology category should not substitute for assessing an individual product’s research.
- Keep persistent symptoms within a qualified-care conversation. The launch account itself distinguishes temporary lubrication or relaxation from treatment of ongoing menopausal changes. For persistent dryness, pain or sleep disruption affecting quality of life, it is not sound to assume that stimulation addresses the underlying cause. Personal decisions about assessment and treatment belong with a qualified healthcare professional. Refemina’s resource on putting sexual symptoms into words for an appointment offers a relevant starting point for that conversation.
The useful decision is not simply whether MenoPulse is “for menopause.” It is whether someone is evaluating an intimate product for enjoyment or looking for help with a persistent concern. Those purposes can coexist, but they call for different kinds of information. Keeping them distinct makes the launch easier to assess without either commercial excitement or unnecessary dismissal.
Why symptom-specific evidence should guide clinical use
For clinical practice, this launch should sharpen questions about intimate-device claims rather than change established care on the strength of a preliminary user study.
How Refemina helps
Placing MenoPulse’s symptom claims beside its appeal as an intimate product is a judgement Refemina supports through clear research interpretation. For women encountering another hormone or supplement sales narrative, Refemina brings sexual wellbeing into the wider midlife picture without treating a purchase as the answer to every concern.
Explore Resources
Sources
- Can sexual stimulation help menopause symptoms
- Menopause Tech Is Getting Smarter About the Symptoms Women Live With
